HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Estrogen receptor-negative breast ductal carcinoma: clinicopathological features and MIB-1 (Ki-67) proliferative index association.

Abstract
Breast cancer estrogen receptor (ER) status is one of the strong additional factors in predicting response of patients towards hormonal treatment. The main aim of this study was to assess the morphological characteristics and proliferative activity using MIB-1(Ki-67) of estrogen receptor negative invasive breast ductal carcinoma (NOS type) as well as to correlate these features with clinicopathological data. We also aim to study the expression of c-erbB2 in ER negative breast tumors. High proliferative rate (MIB-1 above 20%) was observed in 63 (63.6%) of 99 ER negative tumors and that these tumors were associated with high expression of c-erbB2 (57.6%). We observed that MIB-1 is a reliable independent prognostic indicator for ER negative infiltrating ductal carcinoma in this study.
AuthorsNoorasmaliza Mdpaiman, Siti Aishah Md Ali, Reena Mdzin, Meor Zamari Meor Kamal, Wan Anna Md Amin, Mohan Nallusamy, Pavitratha Puspanathan, Rohaizak Muhammad, Sharifa Ezat Wan Puteh, Srijit Das
JournalPloS one (PLoS One) Vol. 9 Issue 2 Pg. e89172 ( 2014) ISSN: 1932-6203 [Electronic] United States
PMID24586570 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Biomarkers, Tumor
  • Ki-67 Antigen
  • Receptors, Estrogen
  • Receptor, ErbB-2
Topics
  • Adult
  • Aged
  • Biomarkers, Tumor (metabolism)
  • Breast Neoplasms (metabolism, pathology)
  • Carcinoma, Ductal, Breast (metabolism, pathology)
  • Female
  • Humans
  • Immunohistochemistry
  • Ki-67 Antigen (metabolism)
  • Middle Aged
  • Prognosis
  • Receptor, ErbB-2 (metabolism)
  • Receptors, Estrogen (metabolism)
  • Young Adult

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: